| Gender | Age (Years) | BMI (kg/m2) | Dose of RLAI (mg) | Pre-9-hydroxyrisperidone (ng/ml) | Post-9-hydroxyrisperidone (ng/ml) | Injection site reactions | Occurrence time | |
| Group-D (N = 13) | F | 56 | 21.7 | 25 | 13.6 | 9.78 | ||
| F | 22 | 21.8 | 37.5 | 13.2 | 11.6 | |||
| M | 70 | 22.7 | 25 | 25.1 | 47.3 | |||
| M | 46 | 22.8 | 50 | 16.7 | 20 | |||
| M | 57 | 23.2 | 50 | 6.93 | 8.33 | |||
| F | 74 | 23.3 | 50 | 25.1 | 15.6 | |||
| M | 69 | 23.8 | 50 | 27.6 | 14.4 | massa) | ||
| M | 60 | 27 | 37.5 | 7.47 | 5.96 | mass | Fifth | |
| M | 57 | 28.2 | 37.5 | 11.5 | 16.4 | |||
| F | 50 | 28.6 | 50 | 10.3 | 10.4 | |||
| M | 62 | 30 | 50 | 7.55 | 7.71 | |||
| F | 58 | 30.7 | 25 | 19.9 | 17.4 | |||
| M | 62 | 32.1 | 50 | 13.4 | 13.7 | |||
| Group-S (N = 13) | M | 56 | 22.1 | 50 | 11.2 | 12 | ||
| M | 56 | 22.7 | 50 | 10.4 | 11.6 | mass | Second | |
| M | 37 | 23.3 | 50 | 8.93 | 9.53 | |||
| M | 40 | 24.2 | 25 | 11 | 7.31 | |||
| F | 59 | 24.5 | 37.5 | 8.8 | 8.38 | |||
| M | 52 | 25.5 | 50 | 67 | 69 | |||
| F | 42 | 27.1 | 50 | 35.6 | 36.7 | |||
| M | 68 | 28.9 | 50 | 31.3 | 24.8 | mass | Fourth | |
| M | 53 | 29.3 | 50 | 20 | 22 | swelling | Second | |
| M | 69 | 30.7 | 25 | 33.6 | 30.7 | swellingb) | ||
| M | 67 | 31.1 | 37.5 | 6.23 | 8.92 | mass | Seventh | |
| F | 62 | 34.2 | 37.5 | 27.1 | 28.6 | |||
| M | 40 | 36.2 | 50 | 8.79 | 4.72 | mass | Fourth |